Half Yearly Report
Half Yearly Report
Brisbane, Feb 19, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4D financial report for the half year ending 31st December 2018.

Highlights for the period include:

- APVMA approval and product application of Detach

- Steven Lydeamore appointed CEO

- Product Development Advisory Board established

- Progression of GaRP dietary supplement development program

To view the full report, please visit:
http://abnnewswire.net/lnk/V5527M9X


About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

    


Contact

General inquiries
Steven Lydeamore
CEO
Anatara Lifesciences
T: +61-438-027-172
E: slydeamore@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au



Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 84) (Last 30 Days: 299) (Since Published: 1869) 
ANALYTICS: LOGIN HERE

Anatara Lifesciences Ltd NEWS: RECENT VISITS (14385)

Research Report

Social Media